AVAX Technologies Presents Results of Phase I-II M-Vax(TM) Trial at Annual Meeting of American Association for Cancer Research.
Business Wire › April 16, 2007
Linked as:
Extract
AVAX Technologies Presents Results of Phase I-II M-Vax(TM) Trial at Annual Meeting of American Association for Cancer Research.
Presentation scheduled for April 16, 2007 at 1:00 PM PST
PHILADELPHIA -- AVAX Technologies, Inc. (OTCMarket:AVXT.OB) today announces that it is presenting the initial results of its Phase I-II trial of M-Vax[TM] for patients with metastatic melanoma at a Clinical Research session of the meeting of the American Association for Canc...See the full content of this document
Sponsored links
